Table 2.
Results after 18 months of treatment.
| Daily clinical practice group (n = 19) | RCT group (n = 23) | Delta | |||||
|---|---|---|---|---|---|---|---|
| t = 0 | t = 18 | Δt = 18 − t = 0 | t = 0 | t = 18 | Δt = 18 − t = 0 | p value | |
| BMI (kg/m2) | 31.0 (27.9–32.8) | 30.5 (26.0–32.4) | −0.36 (−2.10–1.58) | 29.8 (28.1–34.5) | 29.9 (26.3–33.6) | 0.22 (−2.87–1.27) | 0.686 |
| BMI-SDS | 3.23 (3.05–3.64) | 3.00 (2.43–3.37) | −0.15 (−0.54–0.05) | 3.10 (2.72–3.52) | 2.90 (2.34–3.39) | −0.12 (−0.50–0.08) | 0.990 |
| FPG (mmol/l) | 5.0 (4.8–5.6) | 5.4 (5.0–5.7)a | 0.2 (0.0–0.3)a | 4.8 (4.7–5.0) | 4.6 (4.4–4.8) | −0.2 (−0.5–0.0) | 0.001 |
| FPI (μU/ml) | 31.0 (21.0–41.9) | 19.6 (11.0–34.0)a | −5.0 (−20.5–6.3)a | 18.0 (11.0–27.0) | 15.0 (10.0–20.0) | −3.0 (−13.0–6.0) | 0.661 |
| HOMA-IR | 7.16 (4.31–8.96) | 4.29 (2.52–9.43)a | −1.03 (−4.48–1.88)a | 4.00 (2.30–6.36) | 3.00 (2.00–4.29) | −1.00 (−3.17–1.47) | 0.802 |
| HbA1c | 34 (32–39)a | 34 (33–36)a | −1.0 (−3.5–3.5)b | 33 (31–34) | 34 (31–34)c | 1.0 (−1.0–2.3)c | 0.480 |
Data are presented as median (interquartile range). an = 14; bn = 6; cn = 22.
BMI (SDS): body mass index (standard deviation score); FPG: fasted plasma glucose; FPI: fasted plasma insulin; HOMA-IR: homeostasis model assessment for insulin resistance.